Pacific Biosciences of California (NasdaqGS:PACB) Q4 2025 Earnings call February 12, 2026 05:00 PM ET Speaker9Good day, and welcome to PacBio's fourth quarter and full year 2025 earnings conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad, and t ...

Q4 & Full Year 2025 Earnings Presentation February 12, 2026 1 Safe harbor and non-GAAP disclosures Statement regarding use of non‐GAAP financial measures PacBio reports non‐GAAP results for basic net income and loss per share, net income, net loss, gross margins, gross profit and operating expenses in addition to, and not as a substitute for, or because it believes that such information is superior to, financial measures calculated in accordance with GAAP. PacBio believes that non-GAAP financial information ...

Core Insights - PacBio reported a revenue increase of 14% year-over-year for Q4 2025, reaching $44.6 million, and a total revenue of $160.0 million for FY 2025, up from $154.0 million in FY 2024 [2][11]. Financial Performance - Q4 2025 revenue was $44.6 million, compared to $39.2 million in Q4 2024, marking a 14% increase [2]. - Consumable revenue for Q4 2025 was $21.6 million, up from $18.8 million in Q4 2024, while instrument revenue decreased to $17.3 million from $15.3 million [2]. - Gross profit for Q4 2025 was $16.6 million, compared to $10.1 million in Q4 2024, with a non-GAAP gross margin of 40% in Q4 2025 versus 31% in Q4 2024 [3][6]. - GAAP operating expenses for Q4 2025 totaled $57.8 million, significantly lower than $163.1 million in Q4 2024 [4]. - The GAAP net loss for Q4 2025 was $40.4 million, compared to a net income of $2.4 million in Q4 2024, which included a $154.4 million gain on debt restructuring [4][8]. Annual Results - For FY 2025, GAAP gross profit was $45.8 million, up from $37.3 million in FY 2024, with a non-GAAP gross margin of 40% compared to 33% in FY 2024 [6]. - GAAP operating expenses for FY 2025 were $599.6 million, compared to $511.6 million in FY 2024, while non-GAAP operating expenses decreased to $229.9 million from $289.2 million [7]. - The GAAP net loss for FY 2025 was $546.4 million, compared to a loss of $309.9 million in FY 2024 [8]. Product and Market Developments - The company placed 21 Revio systems and 42 Vega systems in Q4 2025, with a total of 61 Revio and 140 Vega systems placed for the full year [2]. - The annualized Revio pull-through per system was approximately $242,000 in Q4 2025, slightly up from $240,000 in Q4 2024 [2]. - The company highlighted record consumables revenue and growth in the clinical market, positioning itself for future growth with the upcoming launch of the SPRQ-Nx system [11]. Balance Sheet and Cash Position - As of December 31, 2025, the company had cash, cash equivalents, and investments totaling $279.5 million, down from $389.9 million a year earlier [29].

Integration of HiFi Long-Read Whole-Genome Sequencing Expands the Collective Capabilities of iHope’s Global Rare Disease NetworkMENLO PARK, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, long-read sequencing technologies, today announced a collaboration with iHope, a global rare disease genomics program of Genetic Alliance, to integrate PacBio’s HiFi® long-read whole-genome sequencing into iHope’s international network. iHope operates the world’s largest ...

Core Viewpoint - PacBio has completed the sale of select intellectual property and assets related to its short-read DNA sequencing technology to Illumina, Inc., receiving $48.1 million in net cash proceeds from the transaction [1][2]. Group 1: Transaction Details - The transaction involved Illumina assuming certain liabilities and granting a non-exclusive license of specific intellectual property back to PacBio [2]. - The deal was finalized on January 30, 2026 [3]. Group 2: Strategic Focus - In response to challenging macroeconomic conditions, PacBio paused the development of its high-throughput short-read sequencing platform to concentrate on its long-read sequencing innovations [3]. - The sale strengthens PacBio's balance sheet and allows the company to focus on driving the adoption of its long-read sequencing platform, particularly the accelerated development of SPRQ-Nx chemistry [3]. Group 3: Company Overview - PacBio is a leading life science technology company that designs and manufactures advanced sequencing solutions for various research applications, including human germline sequencing, oncology, and infectious disease [4].

Company Performance - Pacific Biosciences of California (PACB) closed at $2.26, reflecting a -4.64% change from the previous day, underperforming the S&P 500's daily loss of 0.43% [1] - Over the past month, PACB shares have gained 26.74%, while the Medical sector has lost 2.36% and the S&P 500 has gained 0.89% [1] Earnings Estimates - The company is expected to release its earnings on February 12, 2026, with projected earnings per share (EPS) of -$0.19, indicating a 5% increase from the same quarter last year [2] - Full-year Zacks Consensus Estimates predict earnings of -$1.89 per share and revenue of $0 million, representing year-over-year changes of -127.71% and 0%, respectively [3] Analyst Insights - Recent changes to analyst estimates for Pacific Biosciences should be monitored, as positive revisions are often seen as a good sign for business outlook [3] - The Zacks Rank system, which includes estimate changes, currently ranks Pacific Biosciences at 3 (Hold), with no changes in the Zacks Consensus EPS estimate over the past month [5] Industry Context - The Medical - Instruments industry, which includes Pacific Biosciences, has a Zacks Industry Rank of 88, placing it in the top 36% of over 250 industries [6] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [6]

Core Viewpoint - The article discusses the importance of understanding the potential for both profit and loss in investment opportunities, emphasizing that past performance does not guarantee future results [2][3]. Group 1 - The author expresses no current stock or derivative positions in any mentioned companies and has no plans to initiate such positions in the near future [1]. - The views presented are subject to change without notice, and there is no obligation to update the information [2]. - The article is intended for educational purposes and should not be construed as an investment advisory or solicitation to buy or sell securities [2][3]. Group 2 - The information provided is based on independent third-party sources, which the author believes to be reliable, but the accuracy of such information cannot be guaranteed [2]. - The article highlights that analysts may include both professional and individual investors who may not be licensed or certified [3].

Core Viewpoint - PacBio will hold a quarterly conference call on February 12, 2026, to discuss its fourth quarter and full year 2025 financial results [1]. Company Overview - PacBio (NASDAQ: PACB) is a leading life science technology company that designs, develops, and manufactures advanced sequencing solutions aimed at resolving genetically complex problems for scientists and clinical researchers [2]. - The company's products and technologies, including HiFi long-read sequencing, cater to a wide range of research applications such as human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications [2]. Conference Call Details - The conference call will take place on Thursday, February 12, 2026, at 5:00 pm Eastern Time (2:00 pm Pacific Time) [2]. - Participants can listen live via the internet or access a replay through PacBio's investor website [2]. - Toll-free and international call-in numbers are provided for participants [2].

Company Performance - Pacific Biosciences of California (PACB) closed at $2.58, reflecting a decrease of -3.37% from the previous day's closing price, underperforming the S&P 500's daily gain of 0.03% [1] - Over the past month, PACB shares have increased by 42.02%, outperforming the Medical sector's slight loss of -0.01% and the S&P 500's gain of 0.6% [1] Earnings Expectations - Analysts anticipate that Pacific Biosciences will report earnings of -$0.19 per share, indicating a year-over-year growth of 5% [2] - For the entire fiscal year, the Zacks Consensus Estimates project earnings of -$1.89 per share and revenue of $0 million, representing changes of -127.71% and 0% from the prior year, respectively [2] Analyst Estimates - Recent changes to analyst estimates for Pacific Biosciences reflect shifting short-term business dynamics, with positive revisions indicating optimism about the business outlook [3] - The Zacks Rank system, which incorporates these estimate changes, provides an actionable rating system for investors [4] Zacks Rank and Industry Performance - The Zacks Rank system ranges from 1 (Strong Buy) to 5 (Strong Sell), with stocks rated 1 delivering an average annual return of +25% since 1988 [5] - Pacific Biosciences currently holds a Zacks Rank of 3 (Hold), with the consensus EPS projection remaining stagnant over the past 30 days [5] - The Medical - Instruments industry, part of the Medical sector, has a Zacks Industry Rank of 92, placing it in the top 38% of all industries [6]

Company Developments - Pacific Biosciences of California, Inc. (PACB) announced that its HiFi whole-genome sequencing technology has been adopted as a first-line approach in a major research effort to study Sudden Unexplained Death in Childhood (SUDC) [1] - The research, led by UW Medicine and Seattle Children's, will sequence trios from 200 families using PacBio's Revio sequencing system with SPRQ-Nx chemistry, enabling comprehensive detection of genetic variation [9] - PACB reported preliminary revenue for the fourth quarter of 2025 of $44.6 million and full year 2025 revenue of $160 million, representing year-over-year growth of 14% and 4%, respectively [3] Market Performance - Following the announcement, PACB shares gained 10.8% in the trading session [3] - Over the last six months, PACB shares have increased by 63.9%, compared to the industry's growth of 11.4% and the S&P 500's rise of 14.8% during the same period [3] - PACB currently has a market capitalization of $643.1 million [6] Technology and Industry Trends - HiFi sequencing is positioned as a first-line approach for complex genetic cases, which is expected to strengthen clinical validation and accelerate adoption [4] - The global long-read sequencing market size was estimated at $538.9 million in 2024 and is projected to reach $1.53 billion by 2030, expanding at a CAGR of 20.12% from 2025 to 2030 [12] - PACB's SPRQ-Nx chemistry enhances the performance of HiFi sequencing by delivering higher throughput, improved data quality, and lower costs, making large-scale whole-genome sequencing studies more practical [10] Future Prospects - The adoption of HiFi sequencing in clinical research is expected to create a recurring revenue stream for PACB as demand for its Revio systems, consumables, and service contracts rises [4] - The new community-developed method, CiFi, enables chromosome-scale, haplotype-resolved genome assemblies from a single sequencing run, addressing limitations of short-read Hi-C [13][14]